Control groups in recent septic shock trials : a systematic review by Pettilä, Ville et al.
Intensive Care Med (2016) 42:1912–1921
DOI 10.1007/s00134-016-4444-y
SYSTEMATIC REVIEW
Control groups in recent septic shock 
trials: a systematic review
Ville Pettilä1,2* , Peter Buhl Hjortrup3, Stephan M. Jakob1, Erika Wilkman2, Anders Perner3,4 and Jukka Takala1
© 2016 Springer-Verlag Berlin Heidelberg and ESICM 
Abstract 
Purpose: The interpretation of septic shock trial data is profoundly affected by patients, control intervention, co-
interventions and selected outcome measures. We evaluated the reporting of control groups in recent septic shock 
trials.
Methods: We searched for original articles presenting randomized clinical trials (RCTs) in adult septic shock patients 
from 2006 to 2016. We included RCTs focusing on septic shock patients with at least two parallel groups and at least 
50 patients in the control group. We selected and evaluated data items regarding patients, control group charac-
teristics, and mortality outcomes, and calculated a data completeness score to provide an overall view of quality of 
reporting.
Results: A total of 24 RCTs were included (mean n = 287 patients and 71 % of eligible patients were randomized). Of 
the 24 studies, 14 (58 %) presented baseline data on vasopressors and 58 % the proportion of patients with elevated 
lactate values. Five studies (21 %) provided data to estimate the proportion of septic shock patients fulfilling the 
Sepsis-3 definition. The mean data completeness score was 19 out of 36 (range 8–32). Of 18 predefined control group 
characteristics, a mean of 8 (range 2–17) were reported. Only 2 (8 %) trials provided adequate data to confirm that 
their control group treatment represented usual care.
Conclusions: Recent trials in septic shock provide inadequate data on the control group treatment and hemo-
dynamic values. We propose a standardized trial dataset to be created and validated, comprising characteristics of 
patient population, interventions administered, hemodynamic values achieved, surrogate organ dysfunction, and 
mortality outcomes, to allow better analysis and interpretation of future trial results.
Keywords: Septic shock, Control group, Randomized, Trial, Reporting, Standardization
Background
Septic shock affects millions of people annually (approxi-
mately 300–700 per 100,000 adult population per year), 
and a recent meta-analysis of observational studies 
indicated that it leads to death in 46 % of cases [1] in spite 
of recent progress in diagnosis and treatment.
In addition to the recently revised definition of septic 
shock [1], future progress requires improved design of 
randomized controlled trials (RCTs). For correct inter-
pretation of the results of RCTs in septic shock, it is 
crucial to report all recommendations and restrictions 
stipulated in the protocol and the main co-interven-
tions performed in the control group. The most impor-
tant issues to be considered are representativeness of 
the study population, control group treatment, pos-
sible misalignment due to titrated treatment in usual 
care [2], detailed description of the given treatment and 
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Take-home message: Recent trials in septic shock provide inadequate 
data on the treatment given the control group and the hemodynamic 
values achieved. We propose a standardized trial dataset comprising 
characteristics of patient population, co-interventions administered, 
hemodynamic values achieved, surrogate organ dysfunction, and 
mortality outcomes.
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co-interventions, and their agreement with guidelines 
and with usual care. A deeper understanding of these fac-
tors may improve the clinical utility of trial results.
Accordingly, we aimed to evaluate information reported 
about the control groups in recent septic shock trials 
[3]. We specifically aimed to evaluate (1) the selection of 
the patient population, (2) the description of treatments 
and co-interventions of the control group, especially 
the hemodynamic treatment and hemodynamic values 
achieved, (3) the mortality outcome measures, (4) the rep-
resentativeness of control groups compared to usual care, 
and (5) the overall completeness of the data reported.
Methods
The search strategy and selection of trials
We searched Pubmed, Scopus, and the Cochrane Central 
Register of Controlled Trials for original articles present-
ing RCTs in adult septic shock patients and published 
during the last 10 years (from February 10, 2006, to Feb-
ruary 10, 2016). The search strategy is presented in the 
ESM. Due to the evolution of publication requirements 
and treatment concepts, we considered earlier trials as 
not representative. Two investigators (V.P. and P.H.) inde-
pendently extracted the pre-selected data items from 
the original papers and supplementary material of these 
trials. We excluded the study if: (1) it was not a parallel-
group randomized trial; (2) it did not include an adult 
septic shock population (less than 75 % of the patients or 
not stated); (3) there were fewer than 50 patients in the 
control group; (4) it was a sub-study or a post hoc analy-
sis; or (5) it was not published in the English language. All 
discrepancies in inclusion and evaluation of the studies 
between the two assessors were registered and discussed.
We used predefined data items and the PICO approach: 
patients (P), intervention (I), control (C), and outcome 
(O), however without assessment of (I), the experimental 
intervention studied.
Patient (P) populations
We extracted numbers of screened, eligible, all rand-
omized, and control group patients. In all trials, patients 
with all inclusion criteria and no pre-defined exclusion 
criteria were considered eligible [4–6], regardless of rea-
sons for missing informed consent or any logistic issues. 
We calculated the following ratios: randomized per 
screened, randomized per eligible, and septic shock per 
randomized patients. We judged the representativeness 
of the control populations based on the proportion of 
included patients per eligible patients. We regarded less 
than 50 % randomization per eligible patients as unclear 
representativeness of the study inclusion and exclusion 
criteria. We evaluated the proportion of patients who at 
baseline (1) had vasopressor infusion to target a mean 
arterial pressure (MAP) of 65 mmHg, (2) had lactate of 
at least 2 mmol/L, and (3) fulfilled both abovementioned 
criteria, as well as (4) whether the trial population was 
representative of a septic shock population according to 
the Sepsis-3 definition (with >50  % of patients fulfilling 
the Sepsis-3 definition of septic shock).
Control (C) group characteristics, interventions, 
and co‑interventions
First, we evaluated (1) whether the trial comprised a 
group of usual care and/or protocolized care, (2) whether 
co-interventions were restricted or recommended, and 
(3) whether the control group was designed to repre-
sent usual care. Second, we evaluated inclusion of base-
line characteristics, intervention characteristics, focus of 
infection, pathogens, basic co-morbidities, co-interven-
tions (mechanical ventilation, renal replacement therapy, 
red blood cell transfusions, inotrope use), daily Sequen-
tial Organ Failure Assessment (SOFA), and hemody-
namic data for the first 24  h after randomization [eight 
items: MAP, central venous pressure, urine output, lac-
tate, norepinephrine (vasopressor) dose and duration, 
administered fluids, and fluid balance]. Additionally, if 
data for the entire 24 h were not reported, we used data 
for the first 6 h, and if not available, we recorded data at 
baseline. We calculated the number of reported items for 
hemodynamic data, and described fluid and vasopres-
sor therapy. Finally, we assessed whether the achieved 
and presented hemodynamic values in the study control 
group were adherent to guidelines. If at least 50 % (4 of 8) 
of predefined hemodynamic items were reported and no 
major deviation from usual care could be detected, the 
study control group was judged as adherent to guidelines.
Outcomes (O)
We included only the most common mortality outcomes 
(hospital, 28-/30-day, and 90-day mortality) in our evalu-
ation of both the control and the intervention groups.
Completeness of the reported data
The data completeness score was calculated based on 33 
data items (Table 1) with a maximum of 36 points: 12 for 
patient population (P1–P12; one point each), 18 for con-
trol group (C1–C18; based on 18 items, one point each), 
and 6 for mortality outcomes (O1–O3; 1 point for report-
ing hospital, 2 points for 28-day/30-day, and 3 points 
for 90-day mortality or longer). Finally, we compared 
the data completeness scores for the two periods earlier 
(from 2006 to 2011) and later (from 2012 to 2015), and 
separately between studies focusing on hemodynamic 
treatment and the others. We used the Mann–Whit-
ney test and considered p < 0.05 as indicating statistical 
significance.
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Results
Selection of trials
The trial selection is presented in Fig.  1. The database 
searches revealed a total of 542 references, of which 498 
were excluded based on the abstract reviews. After review 
of the full text of the remaining 44, an additional 20 trials 
were excluded, 4 of them at the final stage because less 
than 75 % of patients had septic shock [7–10]. For 14 of the 
542 trials (2.6 %) there was initial disagreement regarding 
the reason for exclusion; this was resolved after discussion 
in all cases. Thus, in the final analysis we included 24 origi-
nal articles presenting primary data from 24 RCTs. These 
Table 1 Data items and completeness score for randomized controlled trials in adult septic shock (max 36 points per 33 
items)
For scoring of the data items, see Table 2 (P1–12), Table 3 (C1–C18), and Table 4 (O1–O3 and the summary score)
Items Data completeness score
Patients (P1–P12) Max 12
 P1 Number of screened patients 1
 P2 Number of eligible patients 1
 P3 Number of randomized patients 1
 P4 Proportion (%) of randomized to screened 1
 P5 Proportion (%) of randomized to eligible 1
 P6 Number of septic shock patients in the control group 1
 P7 Total number of patients in the control group 1
 P8 Proportion (%) of septic shock patients in the control group 1
 P9 Proportion (%) of control group patients with norepinephrine (NE) to target mean arterial pressure 
(MAP) of 65 mmHg
1
 P10 Proportion (%) of control group patients with blood lactate >2 mmol/L 1
 P11 Proportion(%) of control group patients with both NE and lactate >2 mmol/L 1
 P12 Studies presenting proportion of patients fulfilling the Sepsis-3 septic shock criteria 1
Control group data (C1–C18) Max 18
 Baseline data (C1–C5)
  C1 Baseline characteristics—adequate 1
  C2 Intervention characteristics—adequate 1
  C3 Focus of infection 1
  C4 Pathogens 1
  C5 Comorbidities 1
 Co-interventions presented (C6–C10)
  C6 Mechanical ventilation 1
  C7 Renal replacement therapy 1
  C8 Red blood cell transfusions 1
  C9 Inotropes 1
  C10 Daily Sequential Organ Failure Assessment (SOFA) 1
 Hemodynamic data for the first 24 h after randomization (C11–C18)
  C11 Mean arterial pressure (MAP) 1
  C12 Central venous pressure (CVP) 1
  C13 Urine output 1
  C14 Lactate 1
  C15 Norepinephrine (vasopressor) dose 1
  C16 Norepinephrine (vasopressor) duration 1
  C17 Total amount of administered fluids 1
  C18 Fluid balance 1
 Outcome data on mortality (O1–O3) Max 6
  O1  Hospital 1
  O2  28-/30-day 2
  O3  90-day 3
Total Max 36
1915
trials enrolled patients between 1991 and 2014 (Table 2). 
Twelve trials were published between 2006 and 2011 [11–
22] and 12 between 2012 and 2015 [4–6, 23–31].
Patient populations
Details on the patient populations are presented in Table 2. 
The 24 RCTs included had an average of 287 patients (and 
71 % of eligible patients). Six studies (25 %) did not follow 
the CONSORT guidelines to provide number of screened 
patients and reasons for exclusions [11, 13, 14, 17, 18, 30]. 
In four (17 %) trials less than 50 % of the eligible patients 
were randomized [4, 6, 12, 16], with the reported ratio var-
ying between 32 and 100 % among all RCTs. Due to exclu-
sion of studies with less than 75 % of septic shock patients, 
the proportion of septic shock patients per included 
patients was high—98 % on average (range 75–100 %).
Fourteen (58 %) trials presented baseline data on vaso-
pressors. In three trials less than 25 % (range 3–22 %) of 
the patients received vasopressor treatment at randomi-
zation [4–6]. The proportion of patients with elevated lac-
tate values was mentioned in 14 of 24 (58 %) trials. Five 
studies (21 %) provided adequate data to estimate the pro-
portion of septic shock patients fulfilling the new Sepsis-3 
definition (>50 % in all of them) [25–28, 31]. The average 
number of reported data items was 9 (range 4–12) of 12.
Control group characteristics, interventions, 
and co‑interventions
The completeness of baseline characteristics, co-mor-
bidities, and co-interventions is presented in Table  3. 
Of the 18 predefined control group data items, a mean 
of 8 (range 2–17) were reported. Focus of infection (in 
96  %), microbiological findings in some detail (71  %), 
and co-morbidities (63  %) were reported in most trials. 
Of 24 trials, 18 (75 %) reported the proportion of control 
group patients with mechanical ventilation at baseline 
(ranging from 5 to 97 %) (Table 3, item MV) and 9 (38 %) 
reported the proportion having renal replacement ther-
apy at baseline (ranging from 0 to 35  %) (Table  3, item 
RRT). Administration of RBCs, day-1 SOFA score, nor-
epinephrine dose and duration, and hemodynamic values 
achieved during the first 24  h (MAP, CVP, UO, lactate, 
fluid balance) were reported in up to one-third of the tri-
als (range regarding each item 8–33 %). The total amount 
of fluids administered in the first 24 h was reported in 9 
of 24 (38 %) trials. The reported hemodynamic values for 
the first 24 h are presented as ESM Table 1. If not avail-
able, substitute data points are marked.
In all but one trial [21], the control group was designed 
to include or represent usual care. Six trials included 
restrictions and four had recommendations for the con-
trol group treatment. We judged that half of the trials had 
a usual care group, and 13/24 had a group with protocol-
ized care as their control group (one trial included both 
groups [4]).
None of the control group protocols or treatment goals 
clearly contradicted current guidelines. The representa-
tiveness of the control populations was judged as unclear 
in 22 of 24 RCTs, mainly due to missing hemodynamic 
data, and in one trial due to deviation from the protocol 
Fig. 1 Flowchart of references
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using high norepinephrine with regard to targeted MAP 
[29]. Thus, 2 of 24 (8 %) trials provided adequate data to 
confirm that their control group treatment was adherent 
to recommended usual care.
Control group outcomes
Each of the mortality outcomes was reported in 42–58 % of 
trials (Table 4). The mean sub-score for mortality outcomes 
was 3 (range 0–6) of 6. Three studies reported all three mor-
tality outcomes [5, 12, 26]. The mean of 28-/30-day mortal-
ity was 32 % and ranged 2.5-fold from 16 % [5] to 43 % [20]. 
The mean (range) of reported 90-day mortality was 39  % 
(19–51 %) (12 studies). In 4 of 5 studies where >50 % ful-
filled the Sepsis -3 criteria for septic shock [32], the reported 
90-mortality (mean, range) was 41 % (24–51 %).
Completeness of the reported data
The average total data completeness score was 19 (range 
8–32) of 36. The data completeness scores for each trial 
are presented in Table  4. Studies published between 
2012 and 2015 (12 studies) had higher scores than stud-
ies published between 2006 and 2011 (12 studies): mean 
24 (range 14–32) versus 15 (range 8–25), p = 0.001. The 
10 studies (5 from 2006 to 2011 [11, 12, 16, 19, 20] and 
5 from 2012 to 2015) [4–6, 29, 30] focusing on hemody-
namic management in septic shock patients did not have 
higher scores than the studies not focusing on hemo-
dynamic treatment: mean 21 (range 10–32) versus 18 
(8–27), p  =  0.37. Three studies reported at least 75  % 
(corresponding to 27 items) of the required data [5, 21, 
29]. The trials with lower (n  =  9) than mean mortality 
Table 4 Reported mortality outcomes (O1–O3) (control group and  experimental group) and  total data completeness 
scores in 24 randomized controlled trials in adult septic shock patients
Data items for reporting (P1–P12, C1–C18, and O1–O3) are explained in detail in Table 1
RCT O1‑Controls 
hospital (%)
O2‑Controls
28/30 day 
(%)
O3‑Controls
90 days (%)
Experimen‑
tal
Hospital (%)
Experimen‑
tal
28/30 day 
(%)
Experimen‑
tal
90 days (%)
Patients 
(P1–P12)
Controls 
(C1–C18)
Outcomes 
(O1–O3)
Total 
score/36
Lin 6 10 0 16
Annane 49 34 50 52 40 52 8 8 6 22
Werdan 37 39 6 6 2 14
Sprung 41 32 44 34 4 5 3 12
Stephens 25 27 10 6 1 17
Russell 39 50 35 44 9 11 5 25
Dhainaut 32 40 5 2 2 9
Palizas 30 28 4 2 2 8
Jones 23 17 8 8 1 17
Patel 43 50 6 2 2 10
Annane 8 4 0 12
Huh 35 34 42 37 8 8 3 19
PROWESS-
SHOCK
24 33 26 34 9 4 5 18
6S 36 43 39 51 9 13 5 27
Schortgen 48 43 12 7 1 20
Annane 44 35 46 45 37 48 12 7 6 25
Joannes-
Boyau
51 50 12 7 3 22
TRISS 43 45 12 9 3 24
PROCESS 19 34 21 32 10 9 4 23
ARISE 16 19 15 15 19 10 14 6 30
PROMISE 29 30 9 11 3 23
SEPSISSPAM 34 42 37 44 10 17 5 32
Lu 29 25 6 7 1 14
Payen 20 24 28 34 12 7 5 24
Mean 33 32 39 33 35 40 8.5 7.7 3.1 19.3
Reported in 
n (%)
10 (42 %) 14 (58 %) 12 (50 %) 10 (38 %) 14 (58 %) 12 (50 %) Max 12 Max 18 Max 6
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rates (Table  4) reported a comparable amount of data 
to that of trials (n  =  13) with a higher mortality rates 
(19.6 vs. 20.1/36). The five trials with >50 % septic shock 
patients (Table  2, P11, Sepsis-3-definition) had a mean 
completeness score of 23/36.
In summary, of the 33 items evaluated, 15 were reported 
in less than 50 % of the trials. Data were frequently miss-
ing for relevant comorbidities, co-interventions (renal 
replacement therapy, red blood cell transfusion, ino-
tropes, total fluids, fluid balance), norepinephrine dose 
for the first 24 h (reported in 17 % of trials) and its dura-
tion, basic hemodynamic values achieved for the first 24 h 
(MAP reported in 33  %, urine output in 8  %, lactate in 
29 % of trials) and development of organ dysfunction.
After the first evaluation, there was disagreement on 41 
of 794 (5.1 %) registered data items, most frequently regard-
ing the method of calculation of eligible patients and the 
adequacy of reported data for estimating the proportion 
of patients fulfilling the Sepsis-3 septic shock criteria. All 
these discrepancies were reconciled in the final evaluation.
Discussion
Main findings
In this systematic review comprising recent large RCTs 
in septic shock, we found that about one-half of the data 
considered necessary for evaluation of the control group 
were reported. Only one-fifth of RCTs provided data on 
baseline vasopressor use and on lactate levels needed to 
evaluate septic shock presence according to the Sepsis-3 
definition. Basic hemodynamic variables for day 1 after 
randomization were reported in up to one-third of trials. 
Only 2 of 24 trials provided adequate data to confirm that 
their control group treatment was adherent to usual care 
according to the current guidelines.
Patient populations
We assessed the representativeness of the patient popu-
lation based on the ratio of randomized per eligible 
patients. The representativeness of four trials [5, 12, 16, 
29] was limited due to less than 50 % of eligible patients 
being randomized. In addition, three recent large studies 
[4–6] included septic shock patients, less than one-fifth 
of whom met the recent definition of septic shock [32]. 
Thus, most available data from previous RCTs might not 
be applicable to septic shock patients with the exception 
of two studies [26, 27] in which more than 75 % had sep-
tic shock according to the Sepsis-3 definition published 
in 2016 after all the RCTs.
Control group characteristics, interventions, 
and co‑interventions
For assessment of trial results, data on baseline charac-
teristics, intervention, infection, and co-interventions are 
crucial. More than one-fourth of the trials did not report 
microbiological findings, co-morbidities, or co-interven-
tions (Table 3). Increased transparency regarding admin-
istered concomitant interventions would allow improved 
interpretation of the results of individual trials. Addition-
ally, by carefully documenting the treatment given and 
analyzing the compliance–effect ratio by site, potential 
impact misattribution may be minimized [33]. None of 
the assessed trials included a clear risk of misalignment 
[2]. Less than half of the papers reported inotropes, and 
one-third reported use of RBCs. Of note, the hemody-
namic data for the first 24 h were reported in the minor-
ity of studies, with only one study reporting all eight 
items [29]. We argue that, when septic shock is treated, 
the variables characterizing septic shock and hemody-
namic treatment given should be reported, including 
duration of vasoactive treatment, both the values and 
timing of lactate measurements (due to its time-depend-
ency), and duration of hyperlactatemia (not reported 
in any trial; see the ESM Table). In general, we found it 
surprising that only two trial reports provided adequate 
data to show their control group adherence to usual care. 
Thus, the reporting of future trials can improve markedly.
Completeness of the reported data
Unexpectedly, especially the data regarding basic hemo-
dynamic variables (such as MAP, central venous pres-
sure, urine output, blood lactate) and treatment given 
over time (such as total fluids, fluid balance achieved, 
vasopressor dose and duration) were inadequate in most 
cases. Notably, reporting was not affected by whether 
vasoactive treatment or hemodynamic management 
in general was studied. Similarly, the standard mortal-
ity outcome measures were reported in only half of the 
studies. Suggested international standardization of clini-
cal outcomes measurement [34] when extended to septic 
shock trials, as recently suggested for perioperative trials 
[35], would provide better comparison of future trials’ 
results.
Limitations and strengths
Our systematic review has some limitations. First, due 
to the heterogeneity and missing hemodynamic data, a 
meta-analysis of published data was not possible. Addi-
tionally, the registered data of previous trials were inad-
equate for post hoc analysis classifications according to 
the recent septic shock definition. Second, the proposed 
dataset has not been used or validated previously. Thus, 
several important aspects may deserve to be added to the 
dataset. Among these are documentation of adequacy 
and time to antimicrobial therapy, duration of septic 
shock before randomization and/or vasopressor therapy, 
adjunctive immunomodulation treatments administered, 
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and surrogate and patient-related important outcomes 
other than mortality. In general, the reporting of the 
abovementioned additional data was infrequent. Third, 
the aims of each RCT may have an effect on the decision 
as to which data are important and should be registered. 
However, we did not find any differences in the complete-
ness of hemodynamic items in RCTs focusing on hemo-
dynamics or those with higher mortality rates compared 
to other RCTs in septic shock patients. Therefore, the 
demonstrated variation in the registered data in the quite 
large RCTs analyzed in septic shock patients seems to be 
determined by factors other than the aims of the RCTs. 
Finally, the number of RCTs included was limited, and 
their patient populations, severity of illness, and studied 
treatments differed. Thus, we did not include analysis of 
inclusion or exclusion criteria, sample size calculations, 
randomization process, the effect of treatments or other 
important items included in the CONSORT checklist 
for RCTs [36]; instead, we focused on the reporting of 
data on patients, interventions, and mortality in control 
groups.
Despite its limitations, we consider this systematic 
review valuable in describing the variability and potential 
flaws in reporting data on control groups in large-scale 
septic shock trials. We are not aware of any previous 
systematic review with this purpose and patient popula-
tion. A previous systematic review in septic patients [37], 
which included 2 of the 24 RCTs in this review, had a dif-
ferent objective, aiming at improving the success rate of 
future septic shock trials, and focused on the design and 
methodology of trials.
Future directions
In addition to the Sepsis-3 definition of septic shock, we 
need more detailed and standardized reporting of RCTs. 
In this paper, we propose a minimum set of items to be 
reported as a first step toward standardizing the report-
ing, and not as a complete and final dataset. A generally 
accepted common electronic septic shock dataset for all 
large-scale RCTs would improve the clinical utility of trial 
results, and provide better options for individual-patient 
meta-analysis to combine the data from separate trials 
more easily. Inclusion of data on time-related values, such 
as lactate and MAP, interventions, and changes in poten-
tial surrogate outcomes, such as daily Sequential Organ 
Failure Assessment (SOFA), not only in RCTs but also in 
cohort studies among septic shock patients, would allow 
use of new statistical time-dependent outcome analyses. 
We consider that inclusion of septic shock patients (on 
vasopressors and with elevated lactate) should take place 
as early as possible, but may not be feasible 24/7, unless 
an option for deferred consent is available.
Conclusions
In this systematic review including recent large RCTs 
among septic shock patients, we found that the reported 
data regarding patient populations, control group char-
acteristics, co-interventions, administered hemodynamic 
treatments, and hemodynamic values achieved, varied 
considerably and were inadequate in many trials. How-
ever, the completeness of reported data has improved 
during the last decade. Few RCTs have included patients 
that fulfilled the current septic shock definition, and very 
few provide adequate data to confirm that the control 
group treatment represents usual care. Thus, we sug-
gest that a standardized dataset will be created, generally 
agreed upon, and validated, after which it may be used 
for reporting in future septic shock trials.
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